CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 597 enrolled
Drug / intervention
tisseel +1 moredrug
Likely dose
tisseel 2 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01613664
NCT01613664Phase 3Completed

Randomized Prospective Clinical Study Evaluating the Usefulness of Fibrin Glue (TISSEEL® KIT) to Prevent Gastric Fistula, Intra Abdominal Haemorrhage and Intra Abdominal Loco Regional Collections After Laparoscopic Sleeve Gastrectomy

Centre Hospitalier Universitaire, Amiens·interventional·Posted Jun 7, 2012·Updated Jul 14, 2020

In Brief

A Phase 3 clinical trial evaluating tisseel and no tisseel for Morbid Obesity. Completed, enrolled 597 participants across 2 sites.

Detailed Summary

Laparoscopic Sleeve Gastrectomy has emerged over the last 20 years as a treatment of choice in the surgical management of patients with morbid obesity. However, this restrictive procedure is accompanied by outcomes such as gastric fistula (5%), postoperative hemorrhage (1%) and intra-abdominal loco regional collections (1%). At present, there is no sufficiently reliable technique to prevent these complications.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMorbid Obesity
CountriesFrance
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 7, 2012
Enrollment StartFeb 1, 2014
Primary CompletionMay 15, 2018
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 14.1 years ago

Interventions

tisseeldrug

The product will be given as a 2 mL bottle per patient, which will be spread along the staple line. If necessary, a second bottle of 2 mL is used. The precautions for use are described in the user manual.

no tisseelother

the surgeon does not applied tissucol during the surgery